The new drug Emdolten company & # 39 is a once-daily tablets in the form of ARV medications that counteract resistance to drugs that are often developed with adult HIV treatment.
Aspen Pharmacare logo. Photo: Package.
JOHANNESBURG – South African pharmaceutical companies Aspen Pharmacare on Monday launched a triple combination pill to treat HIV infection in a country where the virus & # 39 is the most common.
The new drug Emdolten company & # 39 is a once-daily tablet as dolutegravir, an antiviral drug that counteracts the drug resistance that often develops with adult HIV treatment, Aspen said.
The drug also contains lamivudine and tenofovir disoproxil fumarate, along with dolutegravir.
In May, South African Health Products Regulation and the European Medicines Agency issued a warning that recommends that doctors not prescribe dolutegravir for women wishing to become pregnant.
This was followed by preliminary data from a study conducted in Botswana, which has found four cases of neural tube defects in babies born to mothers who became pregnant while taking the drug.
The drug is in brand-name drugs and Tivicay Triumeq, most of which are sold belongs to ViiV Healthcare GlaxoSmithKline block in.
Aspen, which is a & # 39 is a pioneer in the development and production of generic antiretroviral (ARV) in South Africa, says that the use of dolutegravir was safe for men, women, who are not of childbearing age and women of childbearing with oral contraceptive use, adding that these groups represent more than 70% of HIV-infected patients.
"The fact that she (Emdolten) was registered means that SAHPRA convenient, it is safe to take to the public," said Aspen strategic trading executive Stavros Reuters The Nicholas, referring to the South African Health Products Regulatory Authority.
The company launched the Aspen Stavudine – the first public ARV drug in August 2003 – at a time when the country is struggling with high levels of HIV infection.
South Africa has 19% of the global number of people living with HIV, 15% of new cases and 11% of AIDS-related deaths, AIDS Agency & # 39; the United Nations said on its website.
There is no vaccine for HIV / AIDS prevention. Current treatments only help patients manage the disease, but the virus quickly proved Mutating challenge the medical community because it often develops resistance to existing drugs.